The boundaries between survival and nonsurvival at COVID-19 : Experience of tertiary care pandemic hospital
© 2021 John Wiley & Sons Ltd..
OBJECTIVE: Coronavirus disease 2019 (COVID-19) is an emerging, fast-spreading, highly mortal and worldwide infectious disease. The pulmonary system was defined as the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mortality concept of this disease presented with more severe and systemic disease. The present study investigated the relationship between the patient characteristics at the initial hospital administration and fatality in COVID-19 patients.
METHODS: In this retrospective and comparative cohort study, all the 767 hospitalised COVID-19 patients, treated between 18 March and 15 May 2020 in the Covid Clinics of Gulhane Training and Research Hospital in Ankara, Turkey, were evaluated.
RESULTS: The fatality rate was significantly increased in patients with any comorbid disease except asthma. The initial laboratory test results indicated highly significant differences according to the patient's outcome. A multifactor logistic regression analysis was performed to calculate the adjusted odds ratios for predicting patient outcomes. Being older than 60 years increased the death risk with an adjusted OR of 7.2 (95% CI: 2.23-23.51; P = .001). The presence of a cancer and the extended duration of intensive care unit treatment were other significant risk factors for nonsurvival. Azithromycin treatment was determined as significantly reduced the death ratio in these patients (P = .002).
CONCLUSION: It was revealed that being older than 60 years, presence of a cancer and extended duration of ICU treatment were the major risk factors for predicting fatality rate in hospitalised COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
International journal of clinical practice - 75(2021), 9 vom: 05. Sept., Seite e14461 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arslan, Yakup [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 17.08.2021 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ijcp.14461 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32655159X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32655159X | ||
| 003 | DE-627 | ||
| 005 | 20231225194836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ijcp.14461 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1088.xml |
| 035 | |a (DE-627)NLM32655159X | ||
| 035 | |a (NLM)34107117 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arslan, Yakup |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The boundaries between survival and nonsurvival at COVID-19 |b Experience of tertiary care pandemic hospital |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2021 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVE: Coronavirus disease 2019 (COVID-19) is an emerging, fast-spreading, highly mortal and worldwide infectious disease. The pulmonary system was defined as the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mortality concept of this disease presented with more severe and systemic disease. The present study investigated the relationship between the patient characteristics at the initial hospital administration and fatality in COVID-19 patients | ||
| 520 | |a METHODS: In this retrospective and comparative cohort study, all the 767 hospitalised COVID-19 patients, treated between 18 March and 15 May 2020 in the Covid Clinics of Gulhane Training and Research Hospital in Ankara, Turkey, were evaluated | ||
| 520 | |a RESULTS: The fatality rate was significantly increased in patients with any comorbid disease except asthma. The initial laboratory test results indicated highly significant differences according to the patient's outcome. A multifactor logistic regression analysis was performed to calculate the adjusted odds ratios for predicting patient outcomes. Being older than 60 years increased the death risk with an adjusted OR of 7.2 (95% CI: 2.23-23.51; P = .001). The presence of a cancer and the extended duration of intensive care unit treatment were other significant risk factors for nonsurvival. Azithromycin treatment was determined as significantly reduced the death ratio in these patients (P = .002) | ||
| 520 | |a CONCLUSION: It was revealed that being older than 60 years, presence of a cancer and extended duration of ICU treatment were the major risk factors for predicting fatality rate in hospitalised COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Dogan, Deniz |e verfasserin |4 aut | |
| 700 | 1 | |a Ocal, Nesrin |e verfasserin |4 aut | |
| 700 | 1 | |a Koc, Alperen |e verfasserin |4 aut | |
| 700 | 1 | |a Ayaz, Tunahan |e verfasserin |4 aut | |
| 700 | 1 | |a Ozkan, Recep |e verfasserin |4 aut | |
| 700 | 1 | |a Yoruk, Fatma |e verfasserin |4 aut | |
| 700 | 1 | |a Esmer, Meltem Nilsen |e verfasserin |4 aut | |
| 700 | 1 | |a Kosger, Sumeyye |e verfasserin |4 aut | |
| 700 | 1 | |a Kadioglu, Ekin |e verfasserin |4 aut | |
| 700 | 1 | |a Savasci, Umit |e verfasserin |4 aut | |
| 700 | 1 | |a Cuce, Ferhat |e verfasserin |4 aut | |
| 700 | 1 | |a Fidan, Gonca |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Gulden |e verfasserin |4 aut | |
| 700 | 1 | |a Kayahan Satis, Neslihan |e verfasserin |4 aut | |
| 700 | 1 | |a Bilge, Sedat |e verfasserin |4 aut | |
| 700 | 1 | |a Senkal, Serkan |e verfasserin |4 aut | |
| 700 | 1 | |a Tasci, Canturk |e verfasserin |4 aut | |
| 700 | 1 | |a Kayir, Hakan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical practice |d 1998 |g 75(2021), 9 vom: 05. Sept., Seite e14461 |w (DE-627)NLM092403344 |x 1742-1241 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2021 |g number:9 |g day:05 |g month:09 |g pages:e14461 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ijcp.14461 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2021 |e 9 |b 05 |c 09 |h e14461 | ||